Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial Eli Lilly and Company (2026) 3
Acta, Mol
Are GLP-1s safe
Presented for research literature review only Chung PM et al
The average weight loss is around 10% of total body weight which means a patient that is 200 pounds can expect to lose an average of 20 pounds
As with other material medical conditions, accurate disclosures at the underwriting stage may need to be validated at claims time
US$ 25.08
US$ 23.62
US$ 20.57
US$ 21.13
US$ 22.56
